Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to -$443000.0.

  • Pharming's Cost of Revenue fell 10154.43% to -$443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $218.5 million, marking a year-over-year decrease of 1121.75%. This contributed to the annual value of $35.4 million for FY2024, which is 4040.54% up from last year.
  • According to the latest figures from Q3 2025, Pharming's Cost of Revenue is -$443000.0, which was down 10154.43% from $65.6 million recorded in Q2 2025.
  • Over the past 5 years, Pharming's Cost of Revenue peaked at $124.0 million during Q4 2023, and registered a low of -$41.8 million during Q4 2021.
  • In the last 5 years, Pharming's Cost of Revenue had a median value of $27.1 million in 2023 and averaged $33.5 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 11581399.3% in 2022, then crashed by 10154.43% in 2025.
  • Pharming's Cost of Revenue (Quarter) stood at -$41.8 million in 2021, then skyrocketed by 142.07% to $17.6 million in 2022, then skyrocketed by 604.82% to $124.0 million in 2023, then decreased by 4.23% to $118.8 million in 2024, then crashed by 100.37% to -$443000.0 in 2025.
  • Its last three reported values are -$443000.0 in Q3 2025, $65.6 million for Q2 2025, and $34.6 million during Q1 2025.